Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Javara Inc.

Neither a doctor nor a teaching hospital

Research payments

$8,922,683

375 payments

Through program year 2025, Javara Inc. is reported as receiving $8,922,683 in research payments, across 375 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $195,194 44
2024 Research $133,599 42
2023 Research $873,581 51
2022 Research $6,519,669 202
2021 Research $1,042,485 20
2020 Research $158,155 16

Breakdown

Who paid Research payments · program years 2020–2025
  1. Moderna TX, Inc. $5,718,200 232 payments
  2. Janssen Research & Development, LLC $1,982,069 60 payments
  3. Merck Sharp & Dohme Corporation $905,986 29 payments
  4. Amgen Inc. $160,366 8 payments
  5. Medtronic, Inc. $145,155 27 payments
  6. Rhythm Pharmaceuticals, Inc. $6,202 16 payments
  7. RedHill Biopharma Inc. $4,621 2 payments
  8. Mylan Inc. $84 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $3,106,392 68 payments
  2. A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants $1,947,227 45 payments
  3. A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health $1,815,868 102 payments
  4. A Phase 2,3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19. $876,135 19 payments
  5. A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $686,261 23 payments
  6. Cip341 Impact2 $145,155 27 payments
  7. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) $116,028 2 payments
  8. A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age $89,106 16 payments
  9. A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) $22,814 3 payments
  10. A Phase 2,3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19. $19,351 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record